Pam has over 30 years of experience leading global clinical development and operations across Phases 1–3, with a focus on complex diseases including inflammatory bowel disease, rare and pediatric conditions, endocrinology, and infectious disease. Pam was most recently Senior Vice President, Clinical Development & Operations at Sorriso Pharmaceuticals, where she led the planning and execution of an early phase study in patients with ulcerative colitis and developed the Phase 2 IBD program strategy and clinical protocols. Prior to Sorriso, Pam held senior clinical leadership roles at Spruce Biosciences, Amplyx Pharmaceuticals (acquired by Pfizer), and Lumena Pharmaceuticals (a Shire company), where she guided clinical programs across a range of therapeutic areas and stages of development. Earlier in her career, she led global studies in neurology and psychiatry and built deep experience across both biotech and CRO settings. Pam holds a B.S. in Biology from San Diego State University.